Though not an academic health system, Novant Health has historically participated in clinical trials. In 2018, the health system had 426 patients participating in clinical trials.
Dr. Alan Skarbnik with the Novant Health Cancer Institute in Charlotte, North Carolina collaborated on seven abstracts about chronic lymphocytic lymphoma with other researchers across the country.
“It’s an honor to be recognized by the American Society of Hematology for our research around chronic lymphocytic lymphoma,” Skarbnik said. “Novant Health strives to be a center of excellence in this area. We are working to build a more robust clinical research program in order to provide patients access to novel therapies and innovative treatment options.”
Dr. Paulette Bryant and Dr. Jenny McDaniel with the St. Jude Affiliate Clinic at Novant Health Hemby Children’s Hospital in Charlotte, North Carolina, collaborated on one abstract about severe bleeding in hemophilia patients. The St. Jude Affiliate Clinic at Novant Health Hemby Children’s Hospital has been recognized by the Centers for Disease Control and Prevention as a Center of Excellence providing comprehensive hemophilia care for children.
“As a hemophilia treatment center, we’re able to provide access to physicians, nurses, physical therapists and social workers with extensive training in taking care of children with complex blood disorders,” Bryant said. “And being affiliated with St. Jude allows us to participate in groundbreaking clinical trials. Those trials enable us to research new cures while decreasing acute and long-term side effects for patients. We are proud that our research was featured at the American Society of Hematology’s annual meeting.”
The abstracts featuring Novant Health physicians include:
- Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
- Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
- Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
- An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
- Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
- Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis
Subscribe